Canine Lymphoma Treatment—Never a One Size Fits All
1.0 CE Credit Hour / Veterinarians & Veterinary Technicians
Overview:
This 1-hour virtual webinar will discuss how Laverdia CA-1 (verdinexor tabs) fits into the treatment of dogs with lymphoma. We will discuss the mechanism of action, dosing, and adverse events and efficacy of this novel agent. Finally, we will discuss why Laverdia CA-1 should be utilized in the primary care setting.
Learning Objectives:
- Understand SINE class of drugs
- Understand the novel mechanism of action for this Laverdia CA-1
- Understand Laverdia CA-1 efficacy and safety profile and how this differs from traditional chemotherapy.
- Analyze the data which was submitted for conditional approval
- Create a standard SOP for dogs who are diagnosed with large cell lymphoma in your clinic and how Laverdia-CA-1 fits into this.
Craig Clifford, DVM, MS, DACVIM (Oncology)
Dr. Craig Clifford graduated from Mississippi State University College of Veterinary Medicine and received an MS in Animal Science /Virology from the University of Delaware. After completing an internship and a medical oncology residency at the University of Pennsylvania, he became a diplomate of the American College of Veterinary Internal Medicine (Oncology) in 2003. He is a medical oncologist at Bluepearl Malvern. He is active in clinical research within a referral setting and serves as an advisory board member with industry and non-profit foundations. He has authored/co-authored over 70 papers and book chapters and is a frequent lecturer at major veterinary meetings in the USA and abroad. Dr. Clifford is a member of the Mars Veterinary Oncology Advisory Board, has served on many VCS and ACVIM committees, as well as being a member of the Oncology Pathology Working Group, and was an Examiner for the Australian Scientist’s Oncology Specialty Exam.
This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.
This activity is sponsored by Dechra.
